News | July 10, 2009

Blood Vessel Bends, Branches Put Brakes on Statins

July 10, 2009 – New British Heart Foundation (BHF) research(1) revealed today suggests for the first time that the way blood flows through our arteries may boost an antioxidant effect of statin medicines.
The discovery at Imperial College London is the first evidence of biomechanical forces affecting the action of a commonly used drug and could point the way toward new targets to improve artery health throughout the body.

Statins lower harmful LDL cholesterol. In 2008, nearly 50 million statin prescriptions were written for people at high risk of heart attack in England(2), where reports estimate they save nearly 10,000 lives each year(3). The drugs are also thought to have other heart-protective actions, which may include their ability to produce antioxidants in the cells of our arteries by boosting levels of the enzyme heme oxygenase-1 (HO-1).

Researchers in Cardiovascular Sciences at Imperial College London investigated the antioxidant potency of statins in different parts of the circulation by measuring the amount of HO-1 in endothelial cells that line arteries.

Dr. Justin Mason, Dr. Faisal Ali and colleagues discovered in human tissue culture and in mice, the increase in HO-1 induced by the statin was significantly higher in cells exposed to fast and regular blood flow, compared to those cells exposed to sluggish or disrupted blood flow.

"Arteries don't clog up in a uniform way,” said Dr. Mason, who led the team from the National Heart and Lung Institute, Imperial College London at Hammersmith Hospital. “Bends and branches of blood vessels, where blood flow is disrupted and can be sluggish, are much more prone to fatty plaques building up and blocking the artery. What we've shown is that those regions of the arteries most likely to become diseased are the same regions that may not be benefiting maximally from statin treatment – a double whammy. We now hope to use these findings to identify a way to get the most out of statins or to find other ways to switch on protective mechanisms in vulnerable areas of arteries."

Research suggests the cells lining our arteries can sense shear stress exerted by blood flowing past them, and this affects their ability to keep the artery healthy. Straighter sections of arteries, with no branches, tend to have faster blood flow and are more protected from build-up of fatty plaques.

"This research demonstrates how the physical forces inside blood vessels may influence the local action of drugs such as statins,” said professor Peter Weissberg, medical director of BHF. “The findings open avenues of investigation that could lead to greater health benefits of statins being realized. Previous research has revealed that endothelial cells produce protective biological signals in parts of the artery where blood flow is fast and uniform and that this is lost in areas where blood flow is disrupted or nonuniform, leading to build-up of dangerous fatty deposits. This study shows that differing forces of blood flow may also cause the endothelial cells to be less responsive to a potentially protective antioxidant effect of statins.”

The research is published in the Journal of Biological Chemistry.

For more information: www.bhf.org.uk, www.imperial.ac.uk

(1) “Induction of the cytoprotective enzyme heme oxygenase-1 by statins is enhanced in vascular endothelium exposed to laminar shear stress and impaired by disturbed flow,”?Ali F, Zakkar M, Karu K, Lidington EA, Hamdulay SS, Boyle JJ, Zloh M, Bauer A, Haskard DO, Evans PC, Mason JC. J. Biol. Chem., Jul 2009; 284: 18882-18892; doi:10.1074/jbc.M109.009886

(2) NHS Information Centre. “Prescription Cost Analysis 2008,” http://www.ic.nhs.uk/webfiles/publications/PCA%202008/PCA%202008v2.pdf ?NB. The number of prescriptions is not the same as the number of people taking statins. The Department of Health website says that around 2.3 million people are receiving statins in the U.K. http://www.dh.gov.uk/en/Healthcare/Coronaryheartdisease/Statins/index.htm

(3) National Service Frameworks: “Coronary heart disease 10 years on - improving heart care,” Roger Boyle (2007)

Related Content

Vascepa and Statins Significantly Reduce Cardiovascular Events in the REDUCE-IT trial. #AHA #AHA18 #AHA2018
News | Pharmaceuticals | November 13, 2018
A study in the current edition of the New England Journal of Medicine shows that a particular treatment significantly...
Evolocumab Benefits High-Risk Patients With Established Cardiovascular and Chronic Kidney Disease
News | Pharmaceuticals | October 31, 2018
Amgen announced a new Repatha cardiovascular outcomes study (FOURIER) analysis evaluating the effects of Repatha (...
Jardiance Improves Life Expectancy for Adults With Type 2 Diabetes and Cardiovascular Disease
News | Pharmaceuticals | October 11, 2018
Novel results from the landmark EMPA-REG OUTCOME trial suggest that treatment with Jardiance positively impacts life...
Effect of Daily Aspirin on First-Time Heart Attack and Stroke Risk Inconclusive
News | Pharmaceuticals | September 04, 2018
The jury is still out on whether people at moderate risk of a first heart attack or stroke should take daily aspirin to...
Blood Pressure and Cholesterol-lowering Drugs Continue to Improve Survival After a Decade
News | Pharmaceuticals | August 27, 2018
Blood pressure and cholesterol-lowering drugs continue to improve survival in patients with hypertension after more...
Pfizer Announces Positive Topline Results from Phase 3 ATTR-ACT Study
News | Pharmaceuticals | April 06, 2018
Pfizer Inc. announced that the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study met its primary endpoint...
Humanetics Presents Data on Drug to Protect Cardiac Cells From Space-Like Radiation

Photo from NASA

News | Pharmaceuticals | February 01, 2018
February 1, 2018 –Humanetics Corporation (Humanetics) has recently completed two research studies funded by the Natio
Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals | October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
News | Pharmaceuticals | October 04, 2017
October 4, 2017 — MyoKardia Inc.
Overlay Init